Held by 4 specialist biotech funds
High Convergence**Signal Note: Perceptive Advisors Initiates $85.9M Position in Zymeworks** Perceptive's entry into ZYME signals conviction in the company's clinical pipeline, likely driven by upcoming data readouts for its lead program ZW25 (bispecific anti-HER2/HER3) in HER2-low breast cancer and gastric cancer, which could provide near-term catalysts and expand addressable market beyond HER2-positive disease.
AI analyst context — unlock full analysis
# Signal Note: BVF Partners Initiates $103.7M Position in Zymeworks BVF's entry into ZYME signals conviction in the company's clinical pipeline, likely driven by upcoming data readouts for its lead programs: ZW25 (bispecific HER2-targeting antibody in gastric/breast cancer) and ZW49 (HER2-directed cytotoxic conjugate). The $103.7M stake (5.5% ownership at typical ZYME valuations) reflects confidence in valuation recovery if near-term catalysts—Phase 2/3 trial updates expected in 2024-2025—demonstrate clinical efficacy and commercial potential. Given BVF's concentrated biotech value mandate, this suggests the firm views ZYME's risk/reward as asymmetric despite recent equity underperformance.
+ 2more — see how much conviction went in
See the Full Story